Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 9/1/08 → 8/31/13 |
Financiación
- Tibotec Pharmaceuticals Ltd: 20.848,00 US$
A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects
- Greenberg, Richard (PI)